Tremelimumab Archives - DelveInsight

Tremelimumab

Pharma news
Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102

The US FDA has recently granted Orphan Drug Designation to AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC. Imfinzi, a monoclonal antibody, binds and inhibits ...


Cytotoxic T lymphocyte-associated antigen-4 Market Forecast & Analysis

Cancer is one of the pioneer causes of obliteration. Although a lot of therapies are being developed in this area but still there is a high unmet need. Currently companies are getting inclined towa...


Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

Global Top Players in Intraocular Lens (IOL) Market

 An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...

Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape

Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...

LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.